Alcoholic liver disease

World Journal of Hepatology

Volumn 4, Issue 3, 2012, Pages 81-90

  Bruha, Radan ^a   Dvorak, Karel ^a   Petrtyl, Jaromir ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Alcohol; Alcoholic liver disease; Liver cirrhosis; Liver fibrosis; Steatohepatitis; Steatosis

Indexed keywords

EID: 84871538674     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v4.i3.81     Document Type: Article

References (88)

1. Sherlock S, Dooley J. Diseases of the Liver and Biliary System. 11th ed. Oxford: Blackwell Publishing, 2002: 381-398
2. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46: 827-839
3. Caballeria J. Epidemiological aspects of alcoholic liver disease. In: Rodes J, Benhamou JP, Blei A, Reichen J, Mario Rizzetto, editors. Textbook of Hepatology. Oxford: Blackwell Publishing, 2007: 1129-1134
4. Zhou L, Conner KR, Phillips MR, Caine ED, Xiao S, Zhang R, Gong Y. Epidemiology of alcohol abuse and dependence in rural chinese men. Alcohol Clin Exp Res 2009; 33: 1770-1776
5. Sharma HK, Tripathi BM, Pelto PJ. The evolution of alcohol use in India. AIDS Behav 2010; 14 Suppl 1: S8-S17
6. Pithey A, Parry C. Descriptive systematic review of Sub-Saharan African studies on the association between alcohol use and HIV infection. SAHARA J 2009; 6: 155-169
7. Fisher JC, Cook PA, Sam NE, Kapiga SH. Patterns of alcohol use, problem drinking, and HIV infection among high-risk African women. Sex Transm Dis 2008; 35: 537-544
8. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531-537
9. Barrio E, Tomé S, Rodríguez I, Gude F, Sánchez-Leira J, Pérez-Becerra E, González-Quintela A. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28: 131-136
10. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-850
11. Snow WM, Murray R, Ekuma O, Tyas SL, Barnes GE. Alcohol use and cardiovascular health outcomes: a comparison across age and gender in the Winnipeg Health and Drinking Survey Cohort. Age Ageing 2009; 38: 206-212
12. Harriss LR, English DR, Hopper JL, Powles J, Simpson JA, O'Dea K, Giles GG, Tonkin AM. Alcohol consumption and cardiovascular mortality accounting for possible misclassification of intake: 11-year follow-up of the Melbourne Collaborative Cohort Study. Addiction 2007; 102: 1574-1585
13. Lu XL, Luo JY, Tao M, Gen Y, Zhao P, Zhao HL, Zhang XD, Dong N. Risk factors for alcoholic liver disease in China. World J Gastroenterol 2004; 10: 2423-2426
14. Roizen R, Kerr WC, Fillmore KM. Cirrhosis mortality and per capita consumption of distilled spirits, United States, 1949-94: trend analysis. BMJ 1999; 319: 666-670
15. Kerr WC, Fillmore KM, Marvy P. Beverage-specific alcohol consumption and cirrhosis mortality in a group of English-speaking beer-drinking countries. Addiction 2000; 95: 339-346
16. Marugame T, Yamamoto S, Yoshimi I, Sobue T, Inoue M, Tsugane S. Patterns of alcohol drinking and all-cause mortality: results from a large-scale population-based cohort study in Japan. Am J Epidemiol 2007; 165: 1039-1046
17. Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990; 322: 95-99
18. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, Thurman RG. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999; 117: 942-952
19. Donohue TM. Alcohol-induced steatosis in liver cells. World J Gastroenterol 2007; 13: 4974-4978
20. Song Z, Zhou Z, Deaciuc I, Chen T, McClain CJ. Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease. Hepatology 2008; 47: 867-879
21. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36: 242-252
22. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-111
23. Siu L, Foont J, Wands JR. Hepatitis C virus and alcohol. Semin Liver Dis 2009; 29: 188-199
24. Shen Z, Li Y, Yu C, Shen Y, Xu L, Xu C, Xu G. A cohort study of the effect of alcohol consumption and obesity on serum liver enzyme levels. Eur J Gastroenterol Hepatol 2010; 22: 820-825
25. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27: 44-54
26. Juran BD, Lazaridis KN. Genomics and complex liver disease: Challenges and opportunities. Hepatology 2006; 44: 1380-1390
27. Whitfield JB. Meta-analysis of the effects of alcohol dehydrogenase genotype on alcohol dependence and alcoholic liver disease. Alcohol Alcohol 1997; 32: 613-619
28. Thomasson HR, Crabb DW, Edenberg HJ, Li TK, Hwu HG, Chen CC, Yeh EK, Yin SJ. Low frequency of the ADH2*2 allele among Atayal natives of Taiwan with alcohol use disorders. Alcohol Clin Exp Res 1994; 18: 640-643
29. Edenberg HJ, Dick DM, Xuei X, Tian H, Almasy L, Bauer LO, Crowe RR, Goate A, Hesselbrock V, Jones K, Kwon J, Li TK, Nurnberger JI, O'Connor SJ, Reich T, Rice J, Schuckit MA, Porjesz B, Foroud T, Begleiter H. Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet 2004; 74: 705-714
30. Reed T, Page WF, Viken RJ, Christian JC. Genetic predisposition to organ-specific endpoints of alcoholism. Alcohol Clin Exp Res 1996; 20: 1528-1533
31. Willner IR, Reuben A. Alcohol and the liver. Curr Opin Gastroenterol 2005; 21: 323-330
32. Valenti L, De Feo T, Fracanzani AL, Fatta E, Salvagnini M, Aricò S, Rossi G, Fiorelli G, Fargion S. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. Alcohol Alcohol 2004; 39: 276-280
33. Arteel G, Marsano L, Mendez C, Bentley F, McClain CJ. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol 2003; 17: 625-647
34. Plauth M, Cabré E, Campillo B, Kondrup J, Marchesini G, Schütz T, Shenkin A, Wendon J. ESPEN Guidelines on Parenteral Nutrition: hepatology. Clin Nutr 2009; 28: 436-444
35. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987-990
36. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-1137
37. Mu YP, Ogawa T, Kawada N. Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine-choline-deficient diet. Lab Invest 2010; 90: 245-256
38. Stewart SF, Day CP: Alcoholic liver disease. In: Boyer TD, Wright TL, Manns MP, editors. Zakim and Boyer's Hepatology. A textbook of liver disease. Philalphia: Elsevier 2006: 579-623
39. Reeves HL, Burt AD, Wood S, Day CP. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996; 25: 677-683
40. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719
41. Diehl AM. Liver disease in alcohol abusers: clinical perspective. Alcohol 2002; 27: 7-11
42. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199
43. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005; 42: 700-706
44. Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady. J, Day CP, Hayes PC, Murray LS, Morris AJ. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 1174-1179
45. Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15: 2190-2203
46. Yeshua H, Oren R. Non invasive assessment of liver fibrosis. Ann Transplant 2008; 13: 5-11
47. Willenbring ML, Massey SH, Gardner MB. Helping patients who drink too much: an evidence-based guide for primary care clinicians. Am Fam Physician 2009; 80: 44-50
48. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res 2007; 31: 1208-1217
49. Palmer RB. A review of the use of ethyl glucuronide as a marker for ethanol consumption in forensic and clinical medicine. Semin Diagn Pathol 2009; 26: 18-27
50. Dousa M, Zima T, Bruha R, Svestka T, Petrtyl J. Sensitivity and specificity of CDT in the evaluation of alcohol abuse in cirrhotic patients. Gut 2006; 55: A307
51. Tsukamoto H. Conceptual importance of identifying alcoholic liver disease as a lifestyle disease. J Gastroenterol 2007; 42: 603-609
52. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008; 75: 34-56
53. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; CD004332
54. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996; 91: 1773-1796; discussion 1773-1796
55. Song BJ, Moon KH, Olsson NU, Salem N. Prevention of alcoholic fatty liver and mitochondrial dysfunction in the rat by long-chain polyunsaturated fatty acids. J Hepatol 2008; 49: 262-273
56. Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 24-34
57. Powell WJ, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968; 44: 406-420
58. Morgan MY. The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol Suppl 1994; 2: 335-343
59. Bishayee A, Darvesh AS, Politis T, McGory R. Resveratrol and liver disease: from bench to bedside and community. Liver Int 2010; 30: 1103-1114
60. Alberino F, Gatta A, Amodio P, Merkel C, Di Pascoli L, Boffo G, Caregaro L. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17: 445-450
61. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002; 26: 1SA-138SA
62. Forrest EH, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, Haydon G, O'Grady J, Day CP. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56: 1743-1746
63. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167-1178
64. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-260
65. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648
66. Arora R, Kathuria S, Jalandhara N. Acute renal dysfunction in patients with alcoholic hepatitis. World J Hepatol 2011; 3: 121-124
67. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 15: 1613-1619
68. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; CD007339
69. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, Carbonell N, Renard P, Ramond MJ, Moreau R, Poynard T. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-1762
70. Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010; 16: 4905-4912
71. Braillon A. Severe alcoholic hepatitis: glucocorticoid saves lives and transplantation is promising. World J Gastroenterol 2011; 17: 2454
72. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397
73. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960
74. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-2769
75. Halsted CH. Nutrition and alcoholic liver disease. Semin Liver Dis 2004; 24: 289-304
76. Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, McIlroy K, Donaghy AJ, McCall JL. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology 2008; 48: 557-566
77. Kearns PJ, Young H, Garcia G, Blaschke T, O'Hanlon G, Rinki M, Sucher K, Gregory P. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology 1992; 102: 200-205
78. Cabré E, Rodríguez-Iglesias P, Caballería J, Quer JC, Sánchez-Lombraña JL, Parés A, Papo M, Planas R, Gassull MA. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32: 36-42
79. Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, Ferenci P, Holm E, Vom Dahl S, Müller MJ, Nolte W. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006; 25: 285-294
80. Bruha R, PetrtÝl J, Urbánek P, Svestka T, Kaláb M, Marecek Z. [Long-term pharmacological treatment of portal hypertension]. Cas Lek Cesk 2005; 144 Suppl 1: 63-6666
81. Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987; 317: 1421-1427
82. Morgan TR, Weiss DG, Nemchausky B, Schiff ER, Anand B, Simon F, Kidao J, Cecil B, Mendenhall CL, Nelson D, Lieber C, Pedrosa M, Jeffers L, Bloor J, Lumeng L, Marsano L, McMarch Clain C, Mishra G, Myers B, Leo M, Ponomarenko Y, Taylor D, Chedid A, French S, Kanel G, Murray N, Pinto P, Fong TL, Sather MR. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005; 128: 882-890
83. Parés A, Planas R, Torres M, Caballería J, Viver JM, Acero D, Panés J, Rigau J, Santos J, Rodés J. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28: 615-621
84. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 2002; 113: 506-515
85. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 2003; 27: 1765-1772
86. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50: 1294-1306
87. McCallum S, Masterton G. Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria. Alcohol Alcohol 2006; 41: 358-363
88. Ryska M, Trunecka P. [Liver transplantation--present status worldwide and in the Czech Republic]. Cas Lek Cesk 2003; 142: 717-726